Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
Business Wire•05/10/2026•08:00 ET
0
Key Highlights
- ➤ALSTARS trial reaches planned enrollment of 120 participants
- ➤Topline data from 24-week treatment phase expected early Q2 2027
- ➤Additional eligible participants in active screening may still enroll
- ➤COYA 302 combines low-dose IL-2 and CTLA-4 Ig for ALS
Expert Statements
Arun Swaminathan, Chief Executive Officer of Coya Therapeutics
“Having achieved the planned enrollment, ALSTARS has reached an important milestone as we advance toward the first randomized, placebo-controlled efficacy data for COYA 302 in ALS”
Arun Swaminathan, Chief Executive Officer of Coya Therapeutics
“We believe this study will provide important insights into whether our dual immunomodulatory approach can potentially slow disease progression in people living with ALS.”
Arun Swaminathan, Chief Executive Officer of Coya Therapeutics
“We remain focused on rigorous execution of this trial and look forward to the topline readout in early Q2 2027.”
Erez Israeli, Chief Executive Officer of Dr. Reddy’s Laboratories Ltd.
“We are pleased with the continued progress of the COYA 302 ALS program and our collaboration with Coya”
Erez Israeli, Chief Executive Officer of Dr. Reddy’s Laboratories Ltd.
“We look forward to completion of the ALSTARS trial and, if approved by regulatory agencies, bringing this novel treatment option to patients and their families impacted by ALS.”
Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
120(th) participant has been enrolled in ALSTARS trial achieving target enrollment
Get started
Create a free account to read the full story.